Saturday, October 3, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleSeeking Alpha· March 8, 2026

Earnings week ahead: ORCL, ADBE, LI, NIO, HPE, ZIM, KSS, and more

View original at seekingalpha.com
Earnings week ahead: ORCL, ADBE, LI, NIO, HPE, ZIM, KSS, and more [Business finance report sales analysis] alexsl Despite a relatively light earnings calendar, the upcoming earnings week will offer investors a broad look across multiple sectors, from technology and EVs to retail, mining, and biotech, as several notable…
Opening lines of the source · Seeking Alpha · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Valuation has compressed to around 11.5× forward non-GAAP P/E, nearly 50% lower than when last rated the stock, largely due to fears of SaaS disruption

    80% confidence
  • Sees roughly 56% upside to $16.72 per share if UiPath delivers another earnings and revenue beat

    80% confidence
  • Management has guided for continued ARR and sales growth in Q4

    80% confidence
  • The upgrade call may be early as Oracle transitions into a more capital-intensive AI infrastructure business, but favorable risk/reward exists after valuation multiples have more than halved since September

    80% confidence
  • Oracle is forming a long-term bottom near its 2025 lows with strong demand for $25B bond sale and $500B+ remaining performance obligation backlog including about $300B tied to OpenAI

    80% confidence
  • Bloom Energy is viewed as offering a stronger solution in the AI data center market compared to FuelCell Energy

    80% confidence
  • Expressing skepticism over Oracle's heavy investment in AI data-center capacity

    80% confidence
  • Despite negative free-cash-flow expectations through 2029, the AI infrastructure buildout and compressed valuation below 20× forward earnings could attract long-term buyers

    80% confidence
  • To avoid a sharp post-earnings selloff, Adobe will need to demonstrate stronger agentic AI integration and raise both revenue and EPS guidance

    80% confidence
  • Gross margins remain in negative territory and the company continues to burn significant amounts of cash

    80% confidence
  • UiPath remains attractively valued following a roughly 24% share price decline, with macro and AI-related concerns appearing overstated given the company's recent performance

    80% confidence
  • Outstanding FCEL shares increased by more than 50% on a quarter-over-quarter basis

    80% confidence
  • Adobe is one of the optically cheapest large-cap tech stocks, trading near 12.4× earnings, but faces intensifying competition from platforms such as Canva, Figma, and Apple

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com